Cancer Core Europe (CCE) Lecture - Ductal Carcinoma in Situ: When cancer isn’t really cancer

Welcome to the next Cancer Core Europe (CCE) Lecture, hosted by the Netherlands Cancer Institute (NKI, Amsterdam):

Ductal Carcinoma in Situ: When cancer isn’t really cancer

Jelle Wesseling, consultant breast pathologist and senior PI at the Netherlands Cancer Institute and professor of breast pathology at Leiden University Medical Center

Zoom link: us02web.zoom.us/j/83723845761

Abstract

Ductal carcinoma in situ (DCIS) now represents 25% of all screen-detected so-called ‘breast cancers’. Yet, most DCIS lesions will never progress to breast cancer. Uncertainty as to which DCIS lesions may progress drives massive overtreatment of this often harmless disease. In this lecture, we will discuss how we unravel DCIS biology, identify biomarkers for DCIS progression risk, and perform clinical research, aiming to prevent the burden of invasive but needless treatment of women diagnosed with harmless DCIS.

What is Cancer Core Europe (CCE)?

Cancer Core Europe is a consortium of seven leading cancer centres (www.cancercoreeurope.eu). CCEs members are driven by a strong will to reshape the cancer research model to ultimately increase the European Union’s competitiveness as a place to conduct cutting-edge research that’s translated to the clinic to deliver more personalized medicine.

What is the content and aim of the CCE Lecture?

The CCE Lecture series is a CCE-internal event, which educates and informs about state-of-the-art research within the seven centers and is aimed to increase awareness among partners about each other’s activities and potential for collaboration.